|
Day 1 - Monday, November 9th, 2009
|
|
Oncology Leaders' Forum 2009
|
R&D Leaders' Forum 2009
|
|
|
Shared morning plenary session
|
|
Proving the value of R&D innovation in an era of healthcare reform and financial stricture
|
Proving the value of R&D innovation in an era of healthcare reform and financial stricture
|
Followed by your choice of four highly interactive parallel sessions:
|
|
Focus session 1
Steering oncology R&D models down the path to competitive advantage, and to the required level of innovation at manageable cost
• How do you accurately define the value proposition of your oncology drug candidate at each stage of the discovery and development process?
|
Workshop
Troubleshooting oncology clinical development on a global basis to overcome patient recruitment challenges in the Western hemisphere
• What are the pros and cons of accessing conducting trials in the US/Europe versus developing regions of the world?
|
Focus session 1
Externalization and networked R&D: Building sustainable, flexible business models by scaling through partnerships and alliances
|
Portfolio management workshop
Optimizing and right-sizing the portfolio to maximize ROI from small molecules and biologics
- How to achieve a healthier spend:outcome ratio
|
Followed by your choice of two parallel sessions:
|
|
Afternoon plenary session
Delivering alternative funding and co-development models to drive oncology R&D
|
Afternoon plenary session
Optimizing the communication of benefit versus risk, and managing the economics of risk management
|
|
|
Day 2 - Tuesday, November 10th, 2009
|
| Oncology Leaders' Forum 2009 |
R&D Leaders' Forum 2009 |
Your choice of two parallel sessions:
|
|
Morning plenary session
Targeting patients and therapies to reduce clinical trial sizes and late-stage attrition rates in oncology
• Optimizing the role of patient selection for activity, and of biomarkers in that patient selection
|
Morning plenary session
Are you adequately prepared and equipped to face the current policy, legal and economic environment?
• Analyzing the macro external factors impacting R&D leadership and decision making
|
Followed by your choice of four highly interactive parallel sessions:
|
|
Focus session
How are trial population enrichment and novel biomarker development strategies impacting clinical costs, timelines and the quality of go/no go R&D decision-making?
|
Workshop
Making the business case for personalized medicine: What will be the keys to ensuring reimbursement for, and a viable ROI from, novel therapeutics with companion diagnostics?
|
Focus session
Size is everything: Optimizing internal organizational and operational models to foster agility, innovation and value driven R&D
|
Workshop
Reducing attrition and achieving faster and cheaper proof of concept through optimal design: Utilizing clinical data to be more predictive in terms of its value
|
Followed by your choice of two parallel sessions:
|
|
Afternoon plenary session
Re-defining our fundamental approach to oncology target identification
|
Afternoon plenary session
Diversification or focused strategies for growth - or both? Where is value to be created next and how will risk of entry be managed?
• Biosimilars, generics, diagnostics, chronic conditions, orphan drugs
|
|
|
Day 3 - Wednesday, November 11th, 2009
|
| Oncology Leaders' Forum 2009 |
R&D Leaders' Forum 2009 |
your choice of two parallel sessions:
|
|
Morning plenary session
Which new targets, technologies and scientific breakthroughs will drive oncology R&D over the coming decade and beyond?
|
Plenary session
Making step changes in the measurement, valuation and improvement of efficiency and productivity: What form of leadership is required to effect a transformation?
• Strategies for pursuing increasingly difficult targets with limited resources
|
|
Followed by your choice of two parallel sessions:
|
|
Focus session
What is the clinical/regulatory model that allows oncology combination therapies to be successfully developed in a realistically cost-effective manner?
|
Workshop
Designing an R&D roadmap for a novel technology area: Cancer stem cells
• Working party (Interactive panel & audience brainstorming session tasked with creating a 'road map' in 120 minutes)
|
